Trial
NCT02520245
Companion Study for Patients Who Completed Participation in a REGN2810 (Anti-PD-1) Clinical Study
Phase IWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
Regeneron Pharmaceuticals
Collaborators
—
Condition
Advanced Malignancies
Intervention
REGN2810
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-11-07